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Abstract
Cardiovascular failure is one of the central therapeutic problems in
patients with severe infection. Although norepinephrine is a potent
and, in most cases, highly effective vasopressor agent, very high
dosages leading to significant side effects can be necessary to
stabilize advanced shock. As a supplementary vasopressor,
arginine vasopressin can reverse hemodynamic failure and
significantly decrease norepinephrine dosages. Whether the
promising possibility of ‘bridging’ advanced septic shock when the
benefit/risk ratio of catecholamine therapy leaves a clinically
tolerable range may improve quantitative and qualitative patient
outcome can only be determined by a large, prospective,
randomized study.
Cardiovascular failure is one of the central therapeutic
problems in patients with severe infection. Current
recommendations for the treatment of septic shock include
volume therapy, and the use of dobutamine and dopamine or
norepinephrine [1]. Although particularly norepinephrine is a
potent and, in most cases, highly effective vasopressor agent,
it cannot stabilize cardiovascular function in some patients
with severe hemodynamic failure and sepsis-mediated
vascular hyposensitivity to endogenous and exogenous
catecholamines [2]. By further increasing norepinephrine
dosages (>0.5–1 µg/kg/min) to guarantee adequate
perfusion pressure at these stages of shock, intensivists often
enter a vicious circle when significant adrenergic side effects
occur that may further deteriorate shock and contribute to an
adverse outcome (tachyarrhythmias, myocardial ischemia,
decreased cardiac output, increased tissue oxygen
consumption, pulmonary hypertension, etc.) [3]. In a minor,
but for the critical care clinician most challenging, portion of
patients with catecholamine-resistant septic shock, therefore,
mortality approaches 80–100%. Correspondingly, more than
one-half of the patients succumbing to sepsis die from
advanced cardiovascular failure in which conventional
catecholamine vasopressor therapy has reached its
therapeutic limits.
Landry and colleagues first reported the successful
stabilization of catecholamine-resistant septic shock by
infusion of arginine vasopressin (AVP) [4]. In response to
this interesting finding, numerous smaller clinical studies
have examined the hemodynamic response to AVP infusion
in advanced septic shock. As concisely summarized in the
review article by Delmas and colleagues [5], most studies
reported the reversal of hypotension after the initiation of
AVP therapy even in the late stages of cardiovascular failure.
Simultaneously, supplementary AVP infusion allowed for a
significant reduction in catecholamine support. High
adrenergic vasopressor dosages could therefore be
decreased into ranges with a tolerable benefit/risk ratio,
where significantly less cardiovascular complications
occurred when compared with high-dose norepinephrine
infusion alone [6]. Moreover, further positive effects of
additional AVP infusion on renal and endocrinologic function
have been reported in patients with septic shock [7–9].
After cardiovascular function has stabilized and
norepinephrine support could be withdrawn to dosages
<0.2–0.3 µg/kg/min, AVP was slowly withdrawn in most
studies. Administered as a supplementary vasopressor agent,
AVP seems to be capable of bridging the phase of advanced
cardiovascular failure and prevent that a vicious circle of high-
dose catecholamine therapy develops. The pivotal issue of
clinical research on the use of AVP in septic shock must
therefore not be the question ‘Can AVP replace
norepinephrine therapy?’, but be the question ‘Can the
supplementary infusion of AVP in addition to norepinephrine
improve the quantitative and qualitative outcome of advanced
septic shock?’.
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Although, as described in this review [5], the cardiovascular
response to AVP infusion in septic shock has been well
reported, the mechanisms of action of AVP remain much less
clear. Since low AVP plasma concentrations have been found
in septic shock patients, AVP infusion was first proposed to
represent hormone replacement therapy rather than
vasopressor therapy [10,11]. Delmas and colleagues are
right to ask how robust such a concept of AVP replacement
in advanced cardiovascular failure is. A recent study
demonstrated that plasma AVP levels were almost always
increased in the initial phase of septic shock, and decreased
thereafter. Accordingly, the relative AVP deficiency and
consequently the suggested indication for AVP hormone
replacement was found only in one-third of late septic shock
patients [12]. Additionally, the increase in arterial pressure
during AVP infusion occurs independently of plasma AVP
concentrations [9,13]. AVP therapy at dosages from 0.01 to
0.1 U/min increases plasma concentrations to 100–250 pg/ml
[9,14], which is 50-fold to 100-fold higher than the AVP
levels reported in patients with cardiogenic shock and septic
shock states still responding to conventional therapy [15].
Therefore, institution of AVP infusion in advanced septic
shock should not be guided by endocrinologic, but by
hemodynamic indications!
Whether the promising possibility of ‘bridging’ advanced
septic shock when the benefit/risk ratio of catecholamine
therapy leaves a tolerable clinical range may also improve
quantitative and qualitative patient outcome can only be
determined by a large, prospective, randomized study. Such a
study will finally also answer the question of whether positive
effects of AVP on macrocirculatory parameters are
outweighed by possible adverse side effects on the
microcirculation system, the hepatosplanchnic system or the
coagulation system. A prospective multicenter study is
currently underway in North America and Australia, with the
first results expected in late 2006. While no data of
supplementary AVP infusion in advanced septic shock on
patient outcome exist, the infusion of AVP in addition to
catecholamine vasopressor agents in order to reduce high,
potentially toxic adrenergic vasopressor dosages can only be
recommended as a last-resort therapy [1].
Delmas and colleagues must be congratulated on their
precise and clinically relevant review article, which excellently
describes the physiological background of AVP. Moreover, it
supplies the critical care clinician with a reasonable overview
of the studies so far published on the use of AVP in septic
shock [5].
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